Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma

J Allergy Clin Immunol. 2018 Apr;141(4):1529-1532.e8. doi: 10.1016/j.jaci.2018.01.008. Epub 2018 Jan 31.

Authors

Affiliations

¹ the Division of Respirology, McMaster University, Hamilton, Ontario, Canada.
² MedImmune LLC, Gaithersburg, Md.
³ Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, Quebec, Canada.
⁴ University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
⁶ the Division of Respirology, McMaster University, Hamilton, Ontario, Canada. Electronic address: parames@mcmaster.ca.

PMID: 29382593
DOI: 10.1016/j.jaci.2018.01.008

No abstract available

Publication types

Clinical Trial, Phase III
Letter
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, CD34 / metabolism
Asthma / drug therapy*
Asthma / metabolism
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / metabolism
Double-Blind Method
Eosinophilia / drug therapy*
Eosinophilia / metabolism
Female
Humans
Immunity, Innate / drug effects
Interleukin-5 / metabolism
Interleukin-5 Receptor alpha Subunit / metabolism
Killer Cells, Natural / drug effects
Killer Cells, Natural / metabolism
Leukocytes, Mononuclear / drug effects
Leukocytes, Mononuclear / metabolism
Lymphocytes / drug effects
Lymphocytes / metabolism
Male
Middle Aged
Prednisone / therapeutic use*
Respiratory System / drug effects*
Respiratory System / metabolism

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal, Humanized
Antigens, CD34
Interleukin-5
Interleukin-5 Receptor alpha Subunit
benralizumab
Prednisone